Huaren Pharmaceutical Co., Ltd.
300110.SZ
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.91B
Close$
$1.09
61.7% downside
Current Fair Value
61.7% downsideOvervalued by 61.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.91 Billion |
|---|---|
| Enterprise Value | $4.71 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.39 |
| Beta | 0.28 |
| Outstanding Shares | 1,182,212,982 |
Return
| Return on Equity | -54.44% |
|---|---|
| Return on Assets | -17.15% |
| Return on Invested Capital | -30.83% |
Valuation & Multiples
| P/E Ratio | -8.25 |
|---|---|
| PEG | 20.15 |
| Price to Sales | 2.85 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 3.62 |
| Enterprise Value to EBIT | -11 |
| Enterprise Value to Net Income | -10 |
| Total Debt to Enterprise | 0.21 |
| Debt to Equity | 1.16 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Huaren Pharmaceutical Co., Ltd.
2,549 employees
CEO: Li Zhiyong Huaren Pharmaceutical Co., Ltd. produces and sells non-PVC soft bag infusions in China. It offers doxofylline, levofloxacin hydrochloride, compound potassium hydrogen phosphate, and caffeine citrate, sodium chloride, glucose, glucose sod...